ImmunityBio, Inc. IBRX Reportable Segment — Income Tax Expense (Benefit)

Similar metrics at other companies

SREReportable Segment — Income tax expense (benefit)

$69M+81.6%

LUMNReportable Segment — Income tax expense (benefit)

$377M+957%

PNW

PNWReportable Segment — Income Tax Expense (Benefit)

-$1M-117%

LOGIReportable Segment — Income Tax Expense (Benefit)

$6.39M—

RDDTReportable Segment — Income tax expense (benefit)

$1.75M+202%

NFLXReportable Segment — Income Tax Expense (Benefit)

$1.26B+291%

Questions, answered.

What is ImmunityBio, Inc.'s reportable segment — income tax expense (benefit)?

ImmunityBio, Inc. (IBRX) reported reportable segment — income tax expense (benefit) of $9K in Q1 2026.

How has ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) changed year-over-year?

ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) increased by 103.8% year-over-year, from -$234K to $9K.

What is the long-term trend for ImmunityBio, Inc.'s reportable segment — income tax expense (benefit)?

Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — income tax expense (benefit) has grown at a 83.7% compound annual growth rate (CAGR), from -$40K to -$135K.

What does reportable segment — income tax expense (benefit) mean?

This metric reflects the income tax expense or benefit specifically allocated to a reportable business segment. It captures the tax implications of the segment's financial results based on the company's internal tax allocation policies or jurisdictional tax requirements. Understanding this helps investors isolate the tax burden associated with specific business activities versus the consolidated corporate tax rate.